Elucidating the Role of the Pluripotency Regulator Prdm14 in Cancer Initiation Using Mouse Models of Lymphoblastic Leukemia
Year: 2021
Type: dissertation
Abstract: Molecular mechanisms underlying high-risk subtypes of leukemia remain elusive. PR-domain containing 14 (Prdm14) is a potent oncogene implicated in the initiation of many cancers, including leukemia. During development, Prdm14 maintains pluripotency by regulating expression of self-renewal and differentiation genes, and promoting global epigenetic changes. Prdm14 expression is restricted to pluripotent cell types; however, PRDM14 is mis-expressed in numerous human cancers and is associated with poor patient outcomes. To understand the molecular mechanisms driving cancer initiation, I studied mouse models of Prdm14-driven leukemia. I characterized a model of T cell acute lymphoblastic leukemia (T-ALL) expressing FLAG-PRDM14 to show PRDM14 binds to the Notch1 locus prior to acquiring Notch1 activating mutations and leukemia onset. Further, I identified CBFA2T3 as the primary protein interaction partner of PRDM14 in leukemic bone marrow (BM), and demonstrated that Cbfa2t3 is required for PRDM14 to expand progenitor-like cells and initiate T-ALL. The interaction between PRDM14 and CBFA2T3 that occurs in conserved family motifs suggests this complex provides a platform to recruit chromatin modifying enzymes to initiate leukemia. I used CyTOF to deeply profile the phenotype of expanded pre-leukemia progenitor-like cells and demonstrated that Prdm14 can initiate parallel cancer programs in different lymphoid lineages. Single-cell RNA-sequencing revealed that pre-leukemic T cells expressed Notch1 and its target genes, while pre-leukemic B-1-like cells expressed AP-1 proto-oncogenes coupled with mis-regulated DNA damage response and cell cycle genes. B-1 cells are an unconventional, self-renewing type of B cell established in early embryogenesis. To test the capacity of Prdm14-expressing pre-leukemic B-1-like cells to initiate leukemia/lymphoma, cells were isolated and injected into syngeneic host mice, leading to B-1 cell leukemia/lymphoma development. Consistently, I showed that Prdm14 can initiate infiltrative B-1 cell leukemia/lymphoma in a second model where Prdm14 expression is restricted to B-lineage committed progenitors, supporting a novel link between Prdm14 and transformation of B-1 cells. These findings are clinically relevant, as relapsed pediatric B-ALL patient tumours that express PRDM14 have significantly worse outcomes. Collectively, my results provide a mechanism for Prdm14-driven cancer initiation in hematopoietic cells that may inform how Prdm14 initiates cancer in solid tumours and how it could be targeted therapeutically.
Source: TSpace (University of Toronto)
Author: Tracey, Lauren Janette
Institution: University of Toronto
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7133087247
